Key facts
- Renaissance BioScience’s last known valuation is $34.3M (Jun 2023).
- It has raised $20.4M; the latest was Later Stage VC ($3.6M) in Sep 2025.
- Notable investors include National Research Council Canada, Radicle (San Diego).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Renaissance BioScience
- ·The full record, as it builds
Funding rounds
No funding rounds for Renaissance BioScience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Renaissance BioScience
Developer of a bioengineering platform designed to create sustainable products across the FoodTech and AgTech sectors using yeast as the primary microbe. The company offers whole-organism and gene-targeted yeast engineering with patented RNA production and oral delivery methods, enabling food, agriculture, and health industries to develop efficient, scalable, and environmentally friendly applications.
- Sector
- Business Products and Services (B2B)
- HQ
- Vancouver, Canada
- Founded
- 2013
- Employees
- 34
- Website
- renaissancebioscience.com/
- Ownership
- Privately Held (backing)
Renaissance BioScience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Renaissance BioScience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Renaissance BioScience in its N-PORT filings yet. We sweep new filings monthly.